Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.36 EUR
Change Today -0.112 / -2.05%
Volume 0.0
CBJ On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:02 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CBJ) Snapshot

Open
€5.48
Previous Close
€5.47
Day High
€5.48
Day Low
€5.36
52 Week High
06/17/15 - €6.80
52 Week Low
08/5/14 - €3.28
Market Cap
90.2M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CUMBERLAND PHARMACEUTICALS (CBJ)

cumberland pharmaceuticals (CBJ) Related Bloomberg News

View More Bloomberg News

cumberland pharmaceuticals (CBJ) Related Businessweek News

No Related Businessweek News Found

cumberland pharmaceuticals (CBJ) Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s products portfolio comprise Acetadote injection for the treatment of acetaminophen poisoning; Caldolor injection for the treatment for pain and fever; Kristalose, a prescription laxative for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and related duodenal ulcer diseases; Vaprisol injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. Its products portfolio also include Hepatoren injection, which is in Phase II clinical trials for the treatment of critically ill hospitalized patients suffering from liver and kidney failure associated with hepatorenal syndrome; and Boxaban oral capsules that is in Phase II clinical trials for the treatment of patients with aspirin-exacerbated respiratory disease. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

85 Employees
Last Reported Date: 03/9/15
Founded in 1999

cumberland pharmaceuticals (CBJ) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $650.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $306.8K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $406.8K
Chief Commercial Officer, Senior Vice Preside...
Total Annual Compensation: $329.5K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $239.3K
Compensation as of Fiscal Year 2014.

cumberland pharmaceuticals (CBJ) Key Developments

Cumberland Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cumberland Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced net revenues of $8,686,774 compared to $8,093,244 for the same period a year ago. Operating income was $4,116 compared to $408,051 for the same period a year ago. Income before income taxes was $44,968 compared to $463,191 for the same period a year ago. Net income was $26,512 compared to $275,182 for the same period a year ago. Net income attributable to common shareholders was $46,281 compared to $286,320 for the same period a year ago. Net cash provided by operating activities was $2,033,821 compared to $982,572 for the same period a year ago. Additions to property and equipment were $108,658 compared to $29,760 for the same period a year ago. Additions to intangible assets were $2,062,321 compared to $388,768 for the same period a year ago. Adjusted earnings were $1,598,402 or $0.09 per diluted share compared to $928,944 or $0.05 per diluted share for the same period a year ago.

Cumberland Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 07, 2015

Cumberland Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 07, 2015

Cumberland Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 07, 2015

Cumberland Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBJ:GR €5.36 EUR -0.112

CBJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $46.11 USD -0.22
Durect Corp $2.35 USD -0.04
Ironwood Pharmaceuticals Inc $10.45 USD -0.02
Pacira Pharmaceuticals Inc/DE $66.42 USD +4.62
Sucampo Pharmaceuticals Inc $21.79 USD +0.89
View Industry Companies
 

Industry Analysis

CBJ

Industry Average

Valuation CBJ Industry Range
Price/Earnings 50.5x
Price/Sales 2.8x
Price/Book 1.3x
Price/Cash Flow 26.4x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit www.cumberlandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.